10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Armistice Capital LLC

Armistice Capital LLC decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 2.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 154,482 shares of the company’s stock after selling 3,804 shares during the quarter. Armistice Capital LLC’s holdings in 10x Genomics were worth $3,005,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in 10x Genomics by 113.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after buying an additional 371 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of 10x Genomics by 74.1% in the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock valued at $37,000 after acquiring an additional 808 shares in the last quarter. Covestor Ltd increased its stake in shares of 10x Genomics by 501.7% during the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock worth $39,000 after acquiring an additional 873 shares during the period. Headlands Technologies LLC purchased a new position in 10x Genomics during the first quarter worth about $71,000. Finally, Federated Hermes Inc. acquired a new stake in 10x Genomics in the second quarter valued at about $136,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $22.30 on Friday. The business’s fifty day moving average price is $21.31 and its two-hundred day moving average price is $24.82. The stock has a market cap of $2.69 billion, a PE ratio of -10.00 and a beta of 1.85. 10x Genomics, Inc. has a one year low of $15.28 and a one year high of $57.90.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.15. 10x Genomics had a negative return on equity of 28.23% and a negative net margin of 37.90%. The business had revenue of $153.10 million for the quarter, compared to analyst estimates of $150.90 million. As a group, equities research analysts predict that 10x Genomics, Inc. will post -1.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Serge Saxonov sold 6,749 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $152,054.97. Following the completion of the transaction, the chief executive officer now owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $152,054.97. Following the completion of the sale, the chief executive officer now owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,351 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares of the company’s stock, valued at $7,788,711.12. The disclosure for this sale can be found here. Insiders have sold 14,061 shares of company stock valued at $316,794 in the last ninety days. Insiders own 10.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Stephens reissued an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a research note on Wednesday, September 4th. Bank of America cut their price objective on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, July 18th. Canaccord Genuity Group reduced their target price on 10x Genomics from $50.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, July 23rd. The Goldman Sachs Group lowered their price target on shares of 10x Genomics from $26.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. Finally, Guggenheim reiterated a “neutral” rating on shares of 10x Genomics in a research note on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Moderate Buy” and an average target price of $31.60.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.